STL Therapy V3.1: Absolute Eradication StrainI: The Chassis – Engineered Circular RNA (e-circRNA)Self-Circularization: Using Permuted Intron-Exon (PIE) sequences, the RNA autocatalytically splices its 5’ and 3’ ends post-transcription.Exonuclease Resistance: Lacking free ends, the e-circRNA evades RNase R degradation, extending half-life from hours to >120 hours in the cytosol.Rolling Circle Translation (RCT): This is our amplification engine. Because the RNA is infinite (circular), the ribosome does not disengage. It continues to translate, producing a concatemeric "super-protein" that is subsequently cleaved into active units by P2A self-cleaving peptides.Efficiency: 1 RNA molecule $\rightarrow$ 1,000+ payload proteins.II: The CPU – Biological Boolean LogicRiboregulators to create a physical AND Gate:$$\text{Activation} = (\text{Input A} \cap \text{Input B}) + \text{Hypoxia}$$The Lock (Toehold Switch): The Ribosome Binding Site (RBS) and Start Codon (AUG) are sequestered within a tight hairpin structure.The Key (OncomiR inputs):Input A: miR-21 (High expression in tumors).Input B: miR-145/155 (Secondary confirmation).The Trigger: Only when both miRNAs bind to the switch does the hairpin unfold, exposing the RBS for translation. This ensures zero leakage in healthy tissue.III: The Payload – The "Triad of Destruction"Once activated, the Rolling Circle Translation churns out a multi-modal arsenal designed to overcome tumor heterogeneity:CRISPR-Cas13b (The RNA Shredder):Unlike Cas9 (which risks permanent DNA damage), Cas13b targets RNA only.It is programmed with gRNAs targeting survival genes (e.g., KRAS-G12C, BCL-2).Collateral Effect: Upon target recognition, Cas13b enters a "frenzy mode," degrading non-target cellular RNA, inducing rapid apoptosis specifically within the cancer cell.Secretable BiTEs (Bi-specific T-cell Engagers):The cancer cell is forced to secrete antibodies that bind CD3 (on T-cells) and EGFR/EpCAM (on neighboring tumor cells).Result: This creates an artificial immune synapse, dragging T-killers into the "cold" tumor microenvironment.shRNA Anti-PD-L1:Silences the immune-checkpoint signal, stripping the tumor of its "don't eat me" mask.IV: Delivery & The "Fail-Safe"How do we deliver this without triggering a cytokine storm?Hybrid Exosome-LNPs (HEL): We cloak synthetic LNPs in mesenchymal stem cell (MSC) exosome membranes.CD47 Enrichment: The surface is engineered with CD47, signaling phagocytes to "stand down," drastically increasing circulation time.iRGD Peptide: Facilitates CendR pathway activation, allowing the nanoparticle to penetrate deep into the dense tumor stroma.The Ultimate Safety Net: The Degron SwitchMechanism: If an adverse event occurs, the patient is administered a standard antibiotic (e.g., Trimethoprim).Action: The drug binds to the Degron tag, inducing immediate ubiquitination and proteasomal degradation of the therapeutic proteins.